Signal strength of reports of Relugolix (Orgovyx®) at the Preferred Term (PT) level.

Saved in:

Bibliographic Details
Main Author:	Ruibo Li (2063167) (author)
Other Authors:	Xi Chen (35903) (author), Yujie Wang (308942) (author)
Published:	2024
Subjects:	Medicine Cell Biology Pharmacology Biotechnology Immunology Cancer Biological Sciences not elsewhere classified ‘ primary suspected take timely prevention reporting odds ratios rare adverse events prostate cancer based may remain undetected avoid serious consequences 26 organ systems adverse events analysis first 30 days unexpected significant aes ps )’ aes aes occurred within market data analysis faers database covering ensure drug safety disproportionality analysis safety information faers database 60 days aes associated treatment measures third quarter side effects potential risks fourth quarter four algorithms comprehensively analyze clinical trials bcpnn ), 397 reports 189 reports
Tags:	Add Tag No Tags, Be the first to tag this record!

Signal strength of reports of Relugolix (Orgovyx<sup>®</sup>) at the Preferred Term (PT) level.